Results 1 to 10 of about 1,612 (203)

Belly dancer syndrome improved by withdrawal of droxidopa and amantadine [PDF]

Clinical Case Reports, 2023
Key Clinical Message A man hospitalized for cerebral infarction developed drug‐induced belly dancer syndrome, which improved after withdrawal of droxidopa and amantadine.
Mihiro Kaga, Hiroyoshi Ueda, Chika Sunagawa, Masashi Oe, Atsushi Shima, Nobuyasu Matsukawa, Takeshi Ueda   +6 more
doaj   +6 more sources

Droxidopa in Critical Care: A Systematic Review of an Emerging Off-Label Practice [PDF]

Critical Care Research and Practice
Background Prolonged use of intravenous (IV) vasopressors in critically ill patients is associated with significant complications. Droxidopa, a norepinephrine precursor approved for neurogenic orthostatic hypotension, has gained interest as an off‐label agent for facilitating vasopressor weaning in ICU settings. This systematic review aimed to evaluate
Carlos Valladares, Franklyn Vega Batista, Marc Faltas, Mareya Menteyas, Katherine Chiapaikeo-Poco   +4 more
doaj   +5 more sources

Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension [PDF]

BMC Neurology, 2017
Background Droxidopa, a prodrug of norepinephrine, was approved for treatment of neurogenic orthostatic hypotension (nOH) due to primary autonomic disorders based on 3 randomized double-blind studies.
Italo Biaggioni, L. Arthur Hewitt, Gerald J. Rowse, Horacio Kaufmann   +3 more
doaj   +4 more sources

Multitargeted docking approach reveals droxidopa against DNA replication and repair-related protein of cervical cancer [PDF]

Scientific Reports
Cervical cancer begins in the cells lining the cervix and is caused by persistent infection with certain types of human papillomavirus (HPV). Initially, it has no symptoms, and later it causes pelvic pain, abnormal vaginal bleeding, and pain during ...
Ahad Amer Alsaiari, Fawaz M. Almufarriji, Ali Hazazi, Daniyah A. Almarghalani, Maha Mahfouz Bakhuraysah, Amani A. Alrehaili, Shatha M. Algethami, Khulood A. Almehmadi, Fayez Saeed Bahwerth, Mohammed Ageeli Hakami   +9 more
doaj   +4 more sources

Characterization of the changes in supine blood pressure with long‐term use of droxidopa in patients with neurogenic orthostatic hypotension [PDF]

Health Science Reports, 2021
Background and Aims Patients with neurogenic orthostatic hypotension (nOH) due to autonomic dysfunction may also experience supine hypertension (defined as supine systolic blood pressure [SBP] ≥140 mmHg).
L. Arthur Hewitt, Annika Lindsten, Stephen Gorny, Meghana Karnik‐Henry, Steven Kymes, Antonella Favit   +5 more
doaj   +2 more sources

Use of droxidopa for blood pressure augmentation after acute spinal cord injury: case reports [PDF]

Acute and Critical Care, 2023
Hypotension secondary to autonomic dysfunction is a common complication of acute spinal cord injury (SCI) that may worsen neurologic outcomes. Midodrine, an enteral α-1 agonist, is often used to facilitate weaning intravenous (IV) vasopressors, but its ...
Christopher S. Hong, Muhammad K. Effendi, Abdalla A. Ammar, Kent A. Owusu, Mahmoud A. Ammar, Andrew B. Koo, Layton A. Lamsam, Aladine A. Elsamadicy, Gregory A. Kuzmik, Maxwell Laurans, Michael L. DiLuna, Mark L. Landreneau   +11 more
doaj   +2 more sources

Droxidopa Persistence in Neurogenic Orthostatic Hypotension May Be Affected by Titration Approach

International Journal of General Medicine, 2021
Fahd Amjad,1 Brett Polenchar,2 Antonella Favit3 1Department of Neurology, Georgetown University Hospital Pasquerilla Healthcare Center, Washington, DC, USA; 2Business Insights, Lundbeck, Deerfield, IL, USA; 3Medical Affairs, Lundbeck, Deerfield, IL ...
Amjad F, Polenchar B, Favit A
doaj   +3 more sources

Combination therapy of midodrine and droxidopa for refractory hypotension in heart failure with preserved ejection fraction per a pharmacist’s proposal: a case report [PDF]

Journal of Pharmaceutical Health Care and Sciences, 2021
Background Patients with chronic heart failure (CHF) are often treated using many diuretics for symptom relief; however, diuretic use may have to continue despite hypotension development in these patients.
Yuki Asai, Tomoaki Sato, Daisuke Kito, Takanori Yamamoto, Iwao Hioki, Yasuhisa Urata, Yasuharu Abe   +6 more
doaj   +2 more sources

Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report [PDF]

Journal of Medical Case Reports, 2020
Background Droxidopa is an oral treatment for the stepwise treatment of neurogenic orthostatic hypotension from autonomic dysfunction. It has been shown to be useful predominantly with neurogenic orthostatic hypotension secondary to Parkinson’s disease ...
Annie H. Ho, Christopher W. Kinter, John Wight, Anudeep R. Neelam, David Krakow   +4 more
doaj   +2 more sources

Computational analysis of RNA methyltransferase Rv3366 as a potential drug target for combating drug-resistant Mycobacterium tuberculosis [PDF]

Frontiers in Molecular Biosciences, 2023
Mycobacterium tuberculosis (M.tb) remains a formidable global health threat. The increasing drug resistance among M.tb clinical isolates is exacerbating the current tuberculosis (TB) burden.
Tasmin Nazim, Vipul Kumar, Faraz Ahmed, Nasreen Z. Ehtesham, Seyed E. Hasnain, Seyed E. Hasnain, Durai Sundar, Sonam Grover   +7 more
doaj   +2 more sources